<DOC>
	<DOCNO>NCT01209130</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label , dose-escalation study DCDT2980S administer intravenous ( IV ) infusion patient relapse refractory hematologic malignancy . In addition , select site , DCDT2980S study combination rituximab .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics Escalating Doses DCDT2980S Patients With Relapsed Refractory B-Cell Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia And DCDT2980S Combination With Rituximab Patients With Relapsed Refractory B-Cell Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Life expectancy least 12 week History histologicallydocumented hematologic malignancy effective standard therapy exist : indolent NHL ( include Grades 13a FL ; MZL [ include splenic , nodal , extranodal ] ; SLL ) , Grade 3b FL , DLBCL , MCL , CLL Must least one bidimensionally measurable lesion Prior use monoclonal antibody antibodydrug conjugate within 4 week prior study treatment Treatment radiotherapy , chemotherapeutic agent , treatment investigational anticancer agent within 2 week prior study treatment Completion autologous stem cell transplant within 100 day prior study treatment Prior allogeneic stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>